Syneos Health (SYNH)
(Delayed Data from NSDQ)
$37.76 USD
+1.84 (5.12%)
Updated Feb 1, 2023 04:00 PM ET
After-Market: $37.72 -0.04 (-0.11%) 7:58 PM ET
5-Strong Sell of 5 5
A Value D Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its growth rate over the past 12 months. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SYNH 37.76 +1.84(5.12%)
Will SYNH be a Portfolio Killer in February?
Zacks Investment Research is releasing its prediction for SYNH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SYNH
Syneos Health (SYNH) Signs New Partnership With Cryoport
Implied Volatility Surging for Syneos Health (SYNH) Stock Options
SYNH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Syneos Health (SYNH) to Launch Serplulimab With New Pact
Syneos Health (SYNH) Hurt by Low Reimbursable Expense, FX Issue
Syneos Health (SYNH) to Enhance Clinical Trials With New Pact
Other News for SYNH
ClearBridge Mid Cap Growth Strategy Q4 2022 Portfolio Manager Commentary
ClearBridge Small Cap Growth Strategy Q4 2022 Portfolio Manager Commentary
ClearBridge Mid Cap Strategy Q4 2022 Portfolio Manager Commentary
ClearBridge Small Cap Value Strategy Q4 2022 Portfolio Manager Commentary
Cryoport Announces New Strategic Partnership with Syneos Health to Advance Cell & Gene Therapies